尊龙凯时 - 人生就是搏!

SENTIS™ Lung cancer/ Colorectal cancer/ Gastric cancer/ GIST Medication Guidance assesses multiple variant types in a single assay by high-throughput sequencing combined with target region probe capture technology, including single nucleotide variant (SNV), Insertions Deletions (InDel), copy number variations (CNV), Fusion. The panel cover the gene testing targets of various drugs which is approved by the FDA, recommended by NCCN guidelines, involved in clinical trials. Providing targeted therapy medication guidance for the patients of lung cancer /colorectal cancer/gastric cancer/gastrointestinal stromal tumors.

Traditional tumor companion diagnostic detection methods mainly include PCR, IHC, FISH. Although PCR can detect gene hotspots in a short time and has high sensitivity and specificity, its throughput are limited. It can only be used to detect common hotspot mutations related to targeted therapy, which is easy to miss some variants and cannot discover new mutations.

FISH can only detect a small number of copy number mutations and cannot discover new fusions.

IHC only detects biomaker related to protein levels, with limited evidence for drug use and relatively single targets.with the developement of NGS, it can overcome the above limitation,comprehensively cover multigenes whcich recomended by FDA ,NCCN guidelines , clinical trials to meet cilinical meets by cost-effective small panel.

Applicable Clinical Scenarios

• Comprehensive 

Comprehensive content design, one workflow for multiple biomarkers.

• Sensitive

High-confidence variant detection, deep sequencing using NGS provides the high sensitivity to reveal somatic variation in tumor subpopulations, identifying somatic mutations as low as 1% variant allele frequency with ≥ 500× minimum coverage.

• Authority  

The detection reagent has obtained CE qualification, somatic variants selected from NCCN guidelines, key opinion leader insights, and pharmaceutical research.

• Enhanced Productivity

Rapid turnaround with going from DNA to report in approximately 2-3.5 calendar days based on DNBSEQ-G99.

• User-Friendly Analysis and Reporting

After the task is created in Halos, it is unattended and directly waits for the analysis results.

• Compatible with multiple applications

BGI Genomics HALOS enables the mixed running of multiple tumor products, and has cross-lane and cross-chip merged analysis functions.

• Flexible throughput  

Target region sequencing of  8/16/32/64 samples can be performed at a time depending on different sequencing platforms.

• Accurate detection

Patented DNB nanoball (DNB) library construction technology and Combinatorial Probe-Anchor Synthesis sequencing technology.

• Safe and reliable

Offline operation, Localized web design and data storage, the account hierarchical management.

【Flyer】SENTIS™ Lung cancer/ Colorectal cancer/ Gastric cancer/ GIST Medication Guidance